CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Cabergoline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02542410
NCT02542410Phase 2Completed
CompareCT.gov

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Boston Children's Hospital·interventional·Posted Sep 7, 2015·Updated Feb 5, 2020

In Brief

A Phase 2 clinical trial evaluating Cabergoline and Norethindrone acetate for Endometriosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 7, 2015
Enrollment StartMay 1, 2016
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.8 years ago

Interventions

Cabergolinedrug

Norethindrone acetatedrug